↑ Grab this Headline Animator

Research And Markets A Recent Survey Of 32 HIV Pipeline Products Phase...

December 23, 2004 -- Currently there is a range of marketed antiretrovirals for the treatment of HIV, the majority of which were launched between the years 1990 to 2000. These are slowly being replaced by products with lower pill burden, higher potency and less incidence of adverse side effects. Those candidates with efficacy against resistant strains or novel having mechanisms of action now dominate the pipeline.



Research and Markets (http://www.researchandmarkets.com/reports/c11345) has announced the addition of Pipeline Insight: HIV - Enter the New Generation Inhibitors to their offering.



The scope of this report is as follows:

- Up to date review and comment of HIV epidemiology, HAART therapy, key drug classes and unmet needs analysis within HIV clinical trial design

- Key HIV pipeline metrics including candidates by phase, class and company participation; discussion of major and new entrant strategies

- Full commercial reappraisal of HIV market with candidate and product global forecasts to 2012; discussion of new combinations and patent expiries

- Expert comment on second generation NRTIs, NNRTIs and PIs. Critical analysis on potential of CCR5 antagonists and CD4 inhibitors



The highlights of this report are as follows:

- A recent survey of 32 HIV pipeline products (Phase I to Phase III) suggests that by 2012, global product sales could amount to just under $12 billion, approximately double the value recorded for 2003 ($5.76 billion).

- In the medium term (2003-2008), 10 product launches are predicted. For the first time, four original NRTI antiretroviral products will also face patent expiry namely, Retrovir, Videx, Hivid and Zerit.

- Within the HIV pipeline, around a third of candidates are classified as entry inhibitors/others. It is predicted that in 2012, 16% of total sales revenue could be derived from these novel compounds. Presently these appear safe and orally available, but major players importantly, are developing more.



Reasons to Purchase this report:

- Access the latest market information and forecasts for current HIV pipeline candidates

- Benchmark internal forecasts, and review's objective appraisals of candidate profiles

- Understand potential HIV company and drug class contribution to revenue growth to 2012



The contents of this report are as follows:

Chapter 1 Executive Summary 3

Chapter 2 Patient Potential 33

Chapter 3 R&D Approach 67

Chapter 4 HIV Pipeline Analysis 80

Chapter 5 Nucleoside Reverse Transcriptase Inhibitors 90

Chapter 6 Non-Nucleoside Reverse Transcriptase Inhibitors

Chapter 7 Protease Inhibitors 178

Chapter 8 Entry Inhibitors 208



For more information visit http://www.researchandmarkets.com/reports/c11345



Laura Wood

Senior Manager

Research and Markets

e-mail protected from spam bots

Fax: +353 1 4100 980

↑ Grab this Headline Animator

---

This article has been robotically scanned and tagged by Prnewsnow with the following search tags. No human manipulation of these tags take place.
| Goodies | Math Goodies | self paced learning |

---

4865 readers online...

, Local News